{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T17:03:51Z","timestamp":1771952631750,"version":"3.50.1"},"reference-count":150,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T00:00:00Z","timestamp":1655337600000},"content-version":"am","delay-in-days":258,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30CA33572"],"award-info":[{"award-number":["P30CA33572"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"US Department of Defense","doi-asserted-by":"publisher","award":["P30CA33572"],"award-info":[{"award-number":["P30CA33572"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA33572"],"award-info":[{"award-number":["P30CA33572"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.canlet.2021.06.004","type":"journal-article","created":{"date-parts":[[2021,6,11]],"date-time":"2021-06-11T12:35:00Z","timestamp":1623414900000},"page":"10-22","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Targeting the mercapturic acid pathway for the treatment of melanoma"],"prefix":"10.1016","volume":"518","author":[{"given":"Sharad S.","family":"Singhal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saumya","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamara","family":"Mirzapoiazova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Horne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjay","family":"Awasthi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravi","family":"Salgia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2021.06.004_bib1","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/978-3-030-41008-7_3","article-title":"Immunotherapy for melanoma","volume":"1244","author":"Albittar","year":"2020","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.canlet.2021.06.004_bib2","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/978-3-030-34025-4_11","article-title":"Melanoma metabolism: cell survival and resistance to therapy","volume":"1219","author":"Lu\u00eds","year":"2020","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.canlet.2021.06.004_bib3","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.4049\/jimmunol.169.6.2907","article-title":"Super-antigen enhancement of specific immunity: antibody production and signaling pathways","volume":"169","author":"Torres","year":"2002","journal-title":"J. Immunol."},{"key":"10.1016\/j.canlet.2021.06.004_bib4","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nri2998","article-title":"Expanding TRAF function: TRAF3 as a tri-faced immune regulator","volume":"11","author":"H\u00e4cker","year":"2011","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.canlet.2021.06.004_bib5","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/sj.cdd.4402085","article-title":"RIP1, a kinase on the crossroads of a cell's decision to live or die","volume":"14","author":"Festjens","year":"2007","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.canlet.2021.06.004_bib6","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1158\/1535-7163.MCT-10-0699","article-title":"Glutathione- conjugate transport by RLIP76 is required for clathrin-dependent endocytosis and chemical carcinogenesis","volume":"10","author":"Singhal","year":"2011","journal-title":"Mol. Canc. Therapeut."},{"key":"10.1016\/j.canlet.2021.06.004_bib7","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.annepidem.2007.01.030","article-title":"Ambient UVB and melanoma risk in the United States: a case-control analysis","volume":"17","author":"Lea","year":"2007","journal-title":"Ann. Epidemiol."},{"key":"10.1016\/j.canlet.2021.06.004_bib8","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nature09666","article-title":"Interferon-\u03b3 links ultraviolet radiation to melanomagenesis in mice","volume":"469","author":"Raza Zaidi","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2021.06.004_bib9","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1038\/sj.onc.1206450","article-title":"Ultraviolet radiation and cutaneous malignant melanoma","volume":"22","author":"Jhappan","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2021.06.004_bib10","first-page":"6724","article-title":"Ink4a\/Arf deficiency promotes ultraviolet radiation-induced melanomagenesis","volume":"62","author":"Recio","year":"2002","journal-title":"Canc. Res."},{"key":"10.1016\/j.canlet.2021.06.004_bib11","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1242\/jcs.109.5.1105","article-title":"Oxidative stress is involved in the UV activation of p53","volume":"109","author":"Renzing","year":"1996","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.canlet.2021.06.004_bib12","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1111\/1523-1747.ep12606994","article-title":"Glutathione plays a key role in the depigmenting and melanocytotoxic action of N-acetyl-4-S-cysteaminylphenol in black and yellow hair follicles","volume":"104","author":"Alena","year":"1995","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.canlet.2021.06.004_bib13","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/1523-1747.ep12313403","article-title":"Glutathione and related enzymes in tumor progression and metastases of human melanoma","volume":"105","author":"Schadendorf","year":"1995","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.canlet.2021.06.004_bib14","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0031-6997(25)06846-2","article-title":"Enzymes and transport systems involved in the formation and disposition of glutathione S-conjugates. Role in bio- activation and detoxication mechanisms of xenobiotics","volume":"47","author":"Commandeur","year":"1995","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.canlet.2021.06.004_bib15","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1158\/0008-5472.CAN-05-3534","article-title":"Regression of melanoma in a murine model by RLIP76 depletion","volume":"66","author":"Singhal","year":"2006","journal-title":"Canc. Res."},{"key":"10.1016\/j.canlet.2021.06.004_bib16","doi-asserted-by":"crossref","first-page":"3408","DOI":"10.1016\/j.febslet.2008.09.001","article-title":"Diminished drug transport and augmented radiation sensitivity caused by loss of RLIP76","volume":"582","author":"Singhal","year":"2008","journal-title":"FEBS Lett."},{"key":"10.1016\/j.canlet.2021.06.004_bib17","first-page":"7","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA A Cancer J. Clin."},{"key":"10.1016\/j.canlet.2021.06.004_bib18","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/jso.22034","article-title":"Systemic treatment of metastatic melanoma: new approaches","volume":"104","author":"Hamid","year":"2011","journal-title":"J. Surg. Oncol."},{"issue":"Suppl 7","key":"10.1016\/j.canlet.2021.06.004_bib19","doi-asserted-by":"crossref","first-page":"vii339","DOI":"10.1093\/annonc\/mdq364","article-title":"Advances in systemic treatment of melanoma","volume":"21","author":"Eggermont","year":"2010","journal-title":"Ann. Oncol.\/ESMO"},{"key":"10.1016\/j.canlet.2021.06.004_bib20","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2021.06.004_bib21","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"BRIM-3 Study Group, Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2021.06.004_bib22","doi-asserted-by":"crossref","first-page":"482","DOI":"10.3390\/cancers12020482","article-title":"Current advances in the treatment of BRAF-mutant melanoma","volume":"12","author":"Patel","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.canlet.2021.06.004_bib23","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1002011","article-title":"Inhibition of mutated, activated BRAF in metastatic melanoma","volume":"363","author":"Flaherty","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2021.06.004_bib24","first-page":"3728","article-title":"Mitogen-actived protein kinase activation is an early event in melanoma progression","volume":"8","author":"Cohen","year":"2002","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.canlet.2021.06.004_bib25","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2174\/157488707780599393","article-title":"Therapeutic strategies for targeting BRAF in human cancer","volume":"2","author":"Pratilas","year":"2007","journal-title":"Rev. Recent Clin. Trials"},{"key":"10.1016\/j.canlet.2021.06.004_bib26","first-page":"6483","article-title":"NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression","volume":"9","author":"Omholt","year":"2003","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.canlet.2021.06.004_bib27","first-page":"6997","article-title":"BRAF and RAS mutations in human lung cancer and melanoma","volume":"62","author":"Brose","year":"2002","journal-title":"Canc. Res."},{"key":"10.1016\/j.canlet.2021.06.004_bib28","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/nature09454","article-title":"Clinical efficacy of a RAF inhibitor needs broad target in BRAF-mutant melanoma","volume":"467","author":"Bollag","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2021.06.004_bib29","doi-asserted-by":"crossref","first-page":"3928","DOI":"10.1158\/0008-5472.CAN-11-2837","article-title":"BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy","volume":"72","author":"Koya","year":"2012","journal-title":"Canc. Res."},{"key":"10.1016\/j.canlet.2021.06.004_bib30","doi-asserted-by":"crossref","first-page":"36945","DOI":"10.18632\/oncotarget.26421","article-title":"Bioenergetic modulation with the mitochondria uncouplers SR4 and niclosamide prevents proliferation and growth of treatment-na\u00efve and vemurafenib-resistant melanomas","volume":"9","author":"Figarola","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2021.06.004_bib31","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/nature09627","article-title":"COT drives resistance to RAF inhibition through MAP kinase pathway reactivation","volume":"468","author":"Johannessen","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2021.06.004_bib32","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/nature09626","article-title":"Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation","volume":"468","author":"Nazarian","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2021.06.004_bib33","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.ccr.2010.11.023","article-title":"Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by co- targeting MEK and IGF-1R\/PI3K","volume":"18","author":"Villanueva","year":"2010","journal-title":"Canc. Cell"},{"key":"10.1016\/j.canlet.2021.06.004_bib34","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.3390\/ijms20061483","article-title":"Targeting the ERK signaling pathway in melanoma","volume":"20","author":"Savoia","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2021.06.004_bib35","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1038\/sj.bjc.6605714","article-title":"Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy","volume":"102","author":"Paraiso","year":"2010","journal-title":"Br. J. Canc."},{"key":"10.1016\/j.canlet.2021.06.004_bib36","doi-asserted-by":"crossref","first-page":"35ra41","DOI":"10.1126\/scitranslmed.3000758","article-title":"Gatekeeper mutations mediate resistance to BRAF-targeted therapies","volume":"2","author":"Whittaker","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.canlet.2021.06.004_bib37","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1200\/JCO.2010.33.2312","article-title":"Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling","volume":"29","author":"Wagle","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2021.06.004_bib38","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s11912-011-0198-4","article-title":"The \u201cSWOT\u201d of BRAF inhibition in melanoma: RAF inhibitors, MEK inhibitors or both?","volume":"13","author":"Nissan","year":"2011","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.canlet.2021.06.004_bib39","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/nature08902","article-title":"RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF","volume":"464","author":"Poulikakos","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2021.06.004_bib40","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.cell.2009.12.040","article-title":"Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF","volume":"140","author":"Heidorn","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2021.06.004_bib41","doi-asserted-by":"crossref","first-page":"15s","DOI":"10.1200\/jco.2010.28.15_suppl.8503","article-title":"Phase I\/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors","volume":"28","author":"Kefford","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2021.06.004_bib42","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1158\/1078-0432.CCR-11-2515","article-title":"BRAF inhibitor GSK2118436 targeted inhibition of mutant BRAF in cancer patients does not impair overall immune competency","volume":"18","author":"Hong","year":"2012","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.canlet.2021.06.004_bib43","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1158\/1078-0432.CCR-10-2200","article-title":"GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition","volume":"17","author":"Gilmartin","year":"2011","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.canlet.2021.06.004_bib44","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1517\/14656566.2013.770475","article-title":"Trametinib (GSK1120212) in the treatment of melanoma","volume":"14","author":"Salama","year":"2013","journal-title":"Expet Opin. Pharmacother."},{"key":"10.1016\/j.canlet.2021.06.004_bib45","doi-asserted-by":"crossref","unstructured":"J.R. Infante, L.A. Fecher, S. Nallapareddy, M.S. Gordon, \u201cSafety and Efficacy Results from the First-In-Human Study of the Oral MEK 1\/2 Inhibitor GSK1120212\u201d, ASCO2010.","DOI":"10.1200\/jco.2010.28.15_suppl.2503"},{"key":"10.1016\/j.canlet.2021.06.004_bib46","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1385\/SCR:1:3:197","article-title":"Leukemia: stem cells, maturation arrest, and differentiation therapy","volume":"1","author":"Sell","year":"2005","journal-title":"Stem Cell Rev."},{"key":"10.1016\/j.canlet.2021.06.004_bib47","doi-asserted-by":"crossref","first-page":"15S","DOI":"10.1200\/jco.2011.29.18_suppl.cra8503","article-title":"Phase I\/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1\/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436)","volume":"29","author":"Infante","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2021.06.004_bib48","doi-asserted-by":"crossref","first-page":"4456","DOI":"10.1200\/JCO.2004.01.185","article-title":"Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer","volume":"22","author":"Rinehart","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2021.06.004_bib49","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1097\/CCO.0b013e32833888ee","article-title":"Mutation-driven drug development in melanoma","volume":"22","author":"Flaherty","year":"2010","journal-title":"Curr. Opin. Oncol."},{"key":"10.1016\/j.canlet.2021.06.004_bib50","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/nature04304","article-title":"BRAF mutation predicts sensitivity to MEK inhibition","volume":"439","author":"Solit","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2021.06.004_bib51","doi-asserted-by":"crossref","first-page":"5281","DOI":"10.1200\/JCO.2005.14.415","article-title":"Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies","volume":"23","author":"Lorusso","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2021.06.004_bib52","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s40257-017-0292-y","article-title":"MEK inhibitors in the treatment of metastatic melanoma and solid tumors","volume":"18","author":"Grimaldi","year":"2017","journal-title":"Am. J. Clin. Dermatol."},{"key":"10.1016\/j.canlet.2021.06.004_bib53","first-page":"383","article-title":"The glutathione S-transferases: a group of multi-functional detoxification protein","volume":"46","author":"Jakoby","year":"1978","journal-title":"Adv. Enzymol. Mol. Biol."},{"key":"10.1016\/j.canlet.2021.06.004_bib54","doi-asserted-by":"crossref","first-page":"445","DOI":"10.3109\/10409239509083491","article-title":"The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance","volume":"30","author":"Hayes","year":"1995","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"key":"10.1016\/j.canlet.2021.06.004_bib55","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1002\/ijc.11260","article-title":"Transport of glutathione- conjugates and chemotherapeutic drugs by RLIP76 (RALBP1): a novel link between G- protein and tyrosine kinase signaling and drug resistance","volume":"106","author":"Awasthi","year":"2003","journal-title":"Int. J. Canc."},{"key":"10.1016\/j.canlet.2021.06.004_bib56","doi-asserted-by":"crossref","first-page":"4372","DOI":"10.1158\/1078-0432.CCR-08-0145","article-title":"RLIP76 and cancer","volume":"14","author":"Awasthi","year":"2008","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.canlet.2021.06.004_bib57","doi-asserted-by":"crossref","first-page":"714","DOI":"10.2337\/db09-0911","article-title":"A central role of RLIP76 in regulation of glycemic control","volume":"59","author":"Awasthi","year":"2010","journal-title":"Diabetes"},{"key":"10.1016\/j.canlet.2021.06.004_bib58","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0024688","article-title":"RLIP76, a glutathione-conjugate transporter, plays a major role in the pathogenesis of metabolic syndrome","volume":"6","author":"Singhal","year":"2011","journal-title":"PloS One"},{"key":"10.1016\/j.canlet.2021.06.004_bib59","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1038\/s41591-019-0476-5","article-title":"Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma","volume":"25","author":"Ribas","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2021.06.004_bib60","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.1158\/1535-7163.MCT-08-0431","article-title":"Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E- mutated melanomas","volume":"7","author":"Smalley","year":"2008","journal-title":"Mol. Canc. Therapeut."},{"key":"10.1016\/j.canlet.2021.06.004_bib61","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.cub.2005.01.031","article-title":"BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma","volume":"15","author":"Patton","year":"2005","journal-title":"Curr. Biol."},{"key":"10.1016\/j.canlet.2021.06.004_bib62","doi-asserted-by":"crossref","first-page":"6574","DOI":"10.1038\/sj.onc.1209674","article-title":"Human melanoma cells expressing V600E B- RAF are susceptible to IGF1R targeting by small interfering RNAs","volume":"25","author":"Yeh","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2021.06.004_bib63","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1158\/1535-7163.MCT-06-0084","article-title":"Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases","volume":"5","author":"Smalley","year":"2006","journal-title":"Mol. Canc. Therapeut."},{"key":"10.1016\/j.canlet.2021.06.004_bib64","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1006\/jtbi.1998.0787","article-title":"Kinetic analysis of the mechanism of action of the multidrug transporter","volume":"195","author":"Ashida","year":"1998","journal-title":"J. Theoretical Biol."},{"key":"10.1016\/j.canlet.2021.06.004_bib65","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1515\/DMDI.2011.015","article-title":"Moving out: from sterol transport to drug resistance - the ABCG subfamily of efflux pumps, Drug Metab","volume":"26","author":"Moitra","year":"2011","journal-title":"Drug Interactions"},{"key":"10.1016\/j.canlet.2021.06.004_bib66","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/1389200043489090","article-title":"ATP hydrolysis-dependent multidrug efflux transporter: MDR1\/P-glycoprotein","volume":"5","author":"Kimura","year":"2004","journal-title":"Curr. Drug Metabol."},{"key":"10.1016\/j.canlet.2021.06.004_bib67","first-page":"713","article-title":"Role of RLIP76 in lung cancer doxorubicin resistance: doxorubicin transport in lung cancer by RLIP76","volume":"22","author":"Awasthi","year":"2003","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.canlet.2021.06.004_bib68","first-page":"721","article-title":"Role of RLIP76 in lung cancer doxorubicin resistance: anti-RLIP76 antibodies trigger apoptosis in lung cancer cells and synergistically increase doxorubicin cytotoxicity","volume":"22","author":"Awasthi","year":"2003","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.canlet.2021.06.004_bib69","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2174\/138920007780655414","article-title":"The non-ABC drug transporter RLIP76 (RALBP-1) plays a major role in the mechanisms of drug resistance","volume":"8","author":"Awasthi","year":"2007","journal-title":"Curr. Drug Metabol."},{"key":"10.1016\/j.canlet.2021.06.004_bib70","doi-asserted-by":"crossref","first-page":"4635","DOI":"10.1016\/j.febslet.2005.07.032","article-title":"The role of PKC\u03b1 and RLIP76 in transport-mediated doxorubicin-resistance in lung cancer","volume":"579","author":"Singhal","year":"2005","journal-title":"FEBS Lett."},{"key":"10.1016\/j.canlet.2021.06.004_bib71","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1002\/ijc.24767","article-title":"Rlip76 transports sunitinib and sorafenib and mediates drug resistance in kidney cancer","volume":"126","author":"Singhal","year":"2010","journal-title":"Int. J. Canc."},{"key":"10.1016\/j.canlet.2021.06.004_bib72","doi-asserted-by":"crossref","first-page":"4382","DOI":"10.1158\/0008-5472.CAN-06-4124","article-title":"Regression of lung and colon cancer xenografts by depleting or inhibiting RLIP76 (RALBP1)","volume":"67","author":"Singhal","year":"2007","journal-title":"Canc. Res."},{"key":"10.1016\/j.canlet.2021.06.004_bib73","doi-asserted-by":"crossref","first-page":"4244","DOI":"10.1158\/0008-5472.CAN-08-3521","article-title":"RLIP76: a target for kidney cancer therapy","volume":"69","author":"Singhal","year":"2009","journal-title":"Canc. Res."},{"key":"10.1016\/j.canlet.2021.06.004_bib74","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.bcp.2008.11.013","article-title":"Regression of prostate cancer xenografts by RLIP76 depletion","volume":"77","author":"Singhal","year":"2009","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.canlet.2021.06.004_bib75","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1002\/mc.22894","article-title":"2'- Hydroxyflavanone inhibits in vitro and in vivo growth of breast cancer cells by targeting RLIP76","volume":"57","author":"Singhal","year":"2018","journal-title":"Mol. Carcinog."},{"key":"10.1016\/j.canlet.2021.06.004_bib76","doi-asserted-by":"crossref","first-page":"6022","DOI":"10.1158\/0008-5472.CAN-05-0968","article-title":"RLIP76 is a major determinant of radiation-sensitivity","volume":"65","author":"Awasthi","year":"2005","journal-title":"Canc. Res."},{"key":"10.1016\/j.canlet.2021.06.004_bib77","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ijrobp.2008.06.1497","article-title":"RLIP76 in defense of radiation poisoning","volume":"72","author":"Singhal","year":"2008","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.canlet.2021.06.004_bib78","doi-asserted-by":"crossref","first-page":"9327","DOI":"10.1021\/bi992964c","article-title":"Novel function of human RLIP76: ATP- dependent transport of glutathione-conjugates and doxorubicin","volume":"39","author":"Awasthi","year":"2000","journal-title":"Biochemistry"},{"key":"10.1016\/j.canlet.2021.06.004_bib79","doi-asserted-by":"crossref","first-page":"16243","DOI":"10.1021\/bi0482811","article-title":"Identification of membrane-anchoring domains of RLIP76 using deletion mutants analyses","volume":"43","author":"Yadav","year":"2004","journal-title":"Biochemistry"},{"key":"10.1016\/j.canlet.2021.06.004_bib80","doi-asserted-by":"crossref","first-page":"4159","DOI":"10.1021\/bi002182f","article-title":"Functional reassembly of xenobiotic-transport from the N-terminal and C- terminal domains of RLIP76 and identification of ATP-binding sequences","volume":"40","author":"Awasthi","year":"2001","journal-title":"Biochemistry"},{"key":"10.1016\/j.canlet.2021.06.004_bib81","first-page":"1133","article-title":"Differential expression of protein kinase C and cAMP- dependent protein kinase in normal human melanocytes and malignant melanomas","volume":"5","author":"Becker","year":"1990","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2021.06.004_bib82","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.bbrc.2006.07.118","article-title":"Mitogenic and drug- resistance mediating effects of PKC\u03b1 require RLIP76","volume":"348","author":"Singhal","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.canlet.2021.06.004_bib83","first-page":"2054","article-title":"RLIP76 silencing inhibits cell proliferation and invasion in melanoma cell line A375","volume":"21","author":"Liu","year":"2017","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.canlet.2021.06.004_bib84","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.biopha.2016.09.022","article-title":"Upregulation of miR-.124 by physcion 8-O-\u03b2-glucopyranoside inhibits proliferation and invasion of malignant melanoma cells via repressing RLIP76","volume":"84","author":"Zhang","year":"2016","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.canlet.2021.06.004_bib85","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/carcin\/bgab016","article-title":"RLIP depletion induces apoptosis associated with inhibition of JAK2\/STAT3 signaling in melanoma cells","volume":"42","author":"Singhal","year":"2021","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.canlet.2021.06.004_bib86","doi-asserted-by":"crossref","first-page":"3162","DOI":"10.1038\/sj.onc.1206455","article-title":"Function and regulation of melanoma-stromal fibroblast interactions: when seeds meet soil","volume":"22","author":"Li","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2021.06.004_bib87","doi-asserted-by":"crossref","unstructured":"K. Forsberg, I. Valyi-Nagy, C.H. Heldin, M. Herlyn, B. Westermark, Platelet-derived growth factor (PDGF) in oncogenesis: development of a vascular connective tissue stroma in xenotransplanted human melanoma producing PDGF-BB, Proc. Natl. Acad. Sci. Unit. States Am. 201(993) 393-397.","DOI":"10.1073\/pnas.90.2.393"},{"key":"10.1016\/j.canlet.2021.06.004_bib88","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s10555-005-1580-1","article-title":"Targeting STAT3 affects melanoma on multiple fronts","volume":"24","author":"Kortylewski","year":"2005","journal-title":"Canc. Metastasis Rev."},{"key":"10.1016\/j.canlet.2021.06.004_bib89","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.1093\/emboj\/cdf351","article-title":"Cytoplasmic transport of Stat3 by receptor-mediated endocytosis","volume":"21","author":"Bild","year":"2002","journal-title":"EMBO J."},{"key":"10.1016\/j.canlet.2021.06.004_bib90","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1158\/0008-5472.CAN-12-0468","article-title":"RALBP1\/RLIP76 depletion in mice suppresses tumor growth by inhibiting tumor neo-vascularization","volume":"72","author":"Lee","year":"2012","journal-title":"Canc. Res."},{"key":"10.1016\/j.canlet.2021.06.004_bib91","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1593\/neo.101080","article-title":"RalBP1 is necessary for metastasis of human cancer cell lines","volume":"12","author":"Wu","year":"2010","journal-title":"Neoplasia"},{"key":"10.1016\/j.canlet.2021.06.004_bib92","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1073\/pnas.1719586115","article-title":"Rlip depletion prevents spontaneous neoplasia in TP53 null mice","volume":"115","author":"Awasthi","year":"2018","journal-title":"Proc. Natl. Acad. Sci. Unit. States Am."},{"key":"10.1016\/j.canlet.2021.06.004_bib93","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0016324","article-title":"The Ras- PI3K signaling pathway is involved in clathrin-independent endocytosis and the internalization of influenza viruses","volume":"6","author":"Fujioka","year":"2011","journal-title":"PloS One"},{"key":"10.1016\/j.canlet.2021.06.004_bib94","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1242\/jcs.110932","article-title":"The signalling factor PI3K is a specific regulator of the clathrin-independent dynamin-dependent endocytosis of IL-2 receptors","volume":"126","author":"Basquin","year":"2013","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.canlet.2021.06.004_bib95","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1074\/jbc.273.2.814","article-title":"Identification and characterization of a novel protein interacting with Ral-binding protein 1, a putative effector protein of Ral","volume":"273","author":"Ikeda","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2021.06.004_bib96","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1000187","article-title":"Regulated RalBP1 binding to RalA and PSD-95 controls AMPA receptor endocytosis and LTD","volume":"7","author":"Han","year":"2009","journal-title":"PLoS Biol."},{"key":"10.1016\/j.canlet.2021.06.004_bib97","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.cell.2008.05.034","article-title":"Endocytic trafficking of rac is required for the spatial restriction of signaling in cell migration","volume":"134","author":"Palamidessi","year":"2008","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2021.06.004_bib98","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/0014-5793(90)81337-N","article-title":"Protein kinase C controls Fc gamma receptor-mediated endocytosis in human neutrophils","volume":"274","author":"Moraru","year":"1990","journal-title":"FEBS Lett."},{"key":"10.1016\/j.canlet.2021.06.004_bib99","doi-asserted-by":"crossref","first-page":"3834","DOI":"10.1038\/sj.emboj.7600847","article-title":"PKCepsilon- mediated phosphorylation of vimentin controls integrin recycling and motility","volume":"24","author":"Ivaska J","year":"2005","journal-title":"EMBO J."},{"key":"10.1016\/j.canlet.2021.06.004_bib100","doi-asserted-by":"crossref","first-page":"18046","DOI":"10.1074\/jbc.M107983200","article-title":"Early endosomal regulation of Smad-dependent signaling in endothelial cells","volume":"277","author":"Panopoulou","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2021.06.004_bib101","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jhep.2010.11.027","article-title":"Distinct role of endocytosis for Smad and non-Smad TGF\u03b2 signaling regulation in hepatocytes","volume":"55","author":"Meyer","year":"2011","journal-title":"J. Hepatol."},{"key":"10.1016\/j.canlet.2021.06.004_bib102","doi-asserted-by":"crossref","first-page":"7117","DOI":"10.1038\/sj.onc.1209701","article-title":"Raf plus TGF- dependent EMT is initiated by endocytosis and lysosomal degradation of E-cadherin","volume":"25","author":"Janda","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2021.06.004_bib103","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0854.2007.00662.x","article-title":"Endocytosis: a positive or a negative influence on Wnt signalling?","volume":"9","author":"Gagliardi","year":"2008","journal-title":"Traffic"},{"key":"10.1016\/j.canlet.2021.06.004_bib104","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1083\/jcb.200401078","article-title":"Endocytosis of E- cadherin regulated by Rac and Cdc42 small G proteins through IQGAP1 and actin filaments","volume":"166","author":"Izumi","year":"2004","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.canlet.2021.06.004_bib105","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1038\/onc.2012.122","article-title":"Identification of a pivotal endocytosis motif in c-Met and selective modulation of HGF-dependent aggressiveness of cancer using the 16-mer endocytic peptide","volume":"32","author":"Cho","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2021.06.004_bib106","doi-asserted-by":"crossref","first-page":"3907","DOI":"10.1038\/ncomms4907","article-title":"Receptor tyrosine kinase c-Met controls the cytoskeleton from different endosomes via different pathways","volume":"5","author":"M\u00e9nard","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2021.06.004_bib107","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/j.1365-2443.2008.01172.x","article-title":"Regulation of clathrin-mediated endocytosis by p53","volume":"13","author":"Endo","year":"2008","journal-title":"Gene Cell."},{"key":"10.1016\/j.canlet.2021.06.004_bib108","article-title":"RLIP controls receptor-ligand signaling by regulating clathrin-dependent endocytosis","author":"Singhal","year":"2021","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.canlet.2021.06.004_bib109","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1242\/jcs.113.16.2837","article-title":"RLIP76, an effector of the GTPase Ral, interacts with the AP2 complex: involvement of the Ral pathway in receptor-endocytosis","volume":"113","author":"Jullien-Flores","year":"2000","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.canlet.2021.06.004_bib110","doi-asserted-by":"crossref","first-page":"30597","DOI":"10.1074\/jbc.M302191200","article-title":"RLIP, an effector of the Ral- GTPases, is a platform for Cdk1 to phosphorylate epsin during the switch off of endocytosis in mitosis","volume":"278","author":"Rosse","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2021.06.004_bib111","doi-asserted-by":"crossref","first-page":"19008","DOI":"10.1074\/jbc.M112472200","article-title":"Regulation of endocytosis of activin type II receptors by a novel PDZ protein through Ral\/Ral-binding protein 1-dependent pathway","volume":"277","author":"Matsuzaki","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2021.06.004_bib112","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0092-8674(00)81959-5","article-title":"Stat3 as an oncogene","volume":"98","author":"Bromberg","year":"1999","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2021.06.004_bib113","doi-asserted-by":"crossref","first-page":"7001","DOI":"10.1038\/sj.onc.1205859","article-title":"Roles of activated Src and Stat3 signaling in melanoma tumor cell growth","volume":"21","author":"Niu","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2021.06.004_bib114","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/jid.2009.213","article-title":"A mutated EGFR is sufficient to induce malignant melanoma with genetic background-dependent histopathologies","volume":"130","author":"Schartl","year":"2010","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.canlet.2021.06.004_bib115","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1002\/ijc.23974","article-title":"UV-induced EGFR signal transactivation is dependent on proligand shedding by activated metalloproteases in skin cancer cell lines","volume":"124","author":"Singh","year":"2009","journal-title":"Int. J. Canc."},{"key":"10.1016\/j.canlet.2021.06.004_bib116","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1093\/annonc\/mdn727","article-title":"High co-expression of both insulin-like growth factor receptor-1 (IGFR-1) and epidermal growth factor receptor (EGFR) is associated with shorter disease-free survival in resected non-small-cell lung cancer patients","volume":"20","author":"Ludovini","year":"2009","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2021.06.004_bib117","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1158\/1078-0432.CCR-06-0776","article-title":"c-Met is a potentially new therapeutic target for treatment of human melanoma","volume":"13","author":"Puri","year":"2007","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.canlet.2021.06.004_bib118","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jid.2020.03.943","article-title":"Treatment of advanced melanoma in 2020 and beyond","volume":"141","author":"Jenkins","year":"2021","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.canlet.2021.06.004_bib119","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1038\/sj.onc.1205260","article-title":"Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis","volume":"21","author":"Niu","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2021.06.004_bib120","doi-asserted-by":"crossref","first-page":"3550","DOI":"10.1038\/sj.onc.1207383","article-title":"Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis","volume":"23","author":"Xie","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2021.06.004_bib121","doi-asserted-by":"crossref","first-page":"7319","DOI":"10.1073\/pnas.131568898","article-title":"Stat3- mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis","volume":"98","author":"Bowman","year":"2001","journal-title":"Proc. Natl. Acad. Sci. Unit. States Am."},{"key":"10.1016\/j.canlet.2021.06.004_bib122","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nrc1275","article-title":"The STATs of cancer--new molecular targets come of age","volume":"4","author":"Yu","year":"2004","journal-title":"Nat. Rev. Canc."},{"key":"10.1016\/j.canlet.2021.06.004_bib123","first-page":"5059","article-title":"Gene therapy with dominant-negative Stat3 suppresses growth of the murine melanoma B16 tumor in vivo","volume":"59","author":"Niu","year":"1999","journal-title":"Canc. Res."},{"key":"10.1016\/j.canlet.2021.06.004_bib124","first-page":"3276","article-title":"Overexpression of a dominant-negative signal transducer and activator of transcription 3 variant in tumor cells leads to production of soluble factors that induce apoptosis and cell cycle arrest","volume":"61","author":"Niu","year":"2001","journal-title":"Canc. Res."},{"key":"10.1016\/j.canlet.2021.06.004_bib125","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1002\/jcb.20876","article-title":"Nuclear- cytoplasmic transport of EGFR involves receptor endocytosis, importin beta1 and CRM1","volume":"98","author":"Lo","year":"2006","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.canlet.2021.06.004_bib126","doi-asserted-by":"crossref","first-page":"31640","DOI":"10.1074\/jbc.273.48.31640","article-title":"Beta-arrestins regulate mitogenic signaling and clathrin-mediated endocytosis of the insulin-like growth factor I receptor","volume":"273","author":"Lin","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2021.06.004_bib127","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1083\/jcb.200807165","article-title":"Survival of the weakest: signaling aided by endosomes","volume":"18","author":"McShane","year":"2008","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.canlet.2021.06.004_bib128","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/34657","article-title":"Induction of epithelial tubules by growth factor HGF depends on the STAT pathway","volume":"391","author":"Boccaccio","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2021.06.004_bib129","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/j.bcp.2012.08.020","article-title":"1,3-bis(3,5-dichlorophenyl) urea compound \u2018COH-SR4\u2019 inhibits proliferation and activates apoptosis in melanoma","volume":"84","author":"Singhal","year":"2012","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.canlet.2021.06.004_bib130","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.3390\/cancers11101556","article-title":"Topical 2\u2032-hydroxyflavanone for cutaneous melanoma","volume":"11","author":"Bose","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.canlet.2021.06.004_bib131","first-page":"509","article-title":"Interaction of glutathione S-transferase M1 and T1 genotypes and malignant melanoma","volume":"10","author":"Kanetsky","year":"2001","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"10.1016\/j.canlet.2021.06.004_bib132","doi-asserted-by":"crossref","first-page":"759","DOI":"10.3109\/02841869509127183","article-title":"Glutathione transferase P1-1 expression in human melanoma metastases: correlation to N-RAS mutations and expression","volume":"34","author":"Platz","year":"1995","journal-title":"Acta Oncol."},{"key":"10.1016\/j.canlet.2021.06.004_bib133","first-page":"4313","article-title":"Glutathione-associated enzymes in anticancer drug resistance","volume":"54","author":"Tew","year":"1994","journal-title":"Canc. Res."},{"key":"10.1016\/j.canlet.2021.06.004_bib134","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/00008390-199211000-00001","article-title":"Expression of glutathione transferase pi in benign and malignant lesions of the melanocyte lineage","volume":"2","author":"Natali","year":"1992","journal-title":"Melanoma Res."},{"key":"10.1016\/j.canlet.2021.06.004_bib135","first-page":"6185","article-title":"Cross-resistance and glutathione-S-transferase-pi levels among four human melanoma cell lines selected for alkylating agent resistance","volume":"49","author":"Wang","year":"1989","journal-title":"Canc. Res."},{"key":"10.1016\/j.canlet.2021.06.004_bib136","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/0006-2952(93)90150-U","article-title":"Doxorubicin resistance in human melanoma cells: MDR-1 and glutathione S-transferase pi gene expression","volume":"45","author":"Ramachandran","year":"1993","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.canlet.2021.06.004_bib137","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1111\/j.1365-2133.2012.10831.x","article-title":"Role of glutathione S-transferases in melanoma susceptibility: association with GSTP1 rs1695 polymorphism","volume":"166","author":"Ibarrola-Villava","year":"2012","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.canlet.2021.06.004_bib138","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/0167-4838(93)90245-M","article-title":"Interactions of glutathione S-transferase \u03c0 with ethacrynic acid and its glutathione conjugate","volume":"1164","author":"Awasthi","year":"1993","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.canlet.2021.06.004_bib139","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1124\/mol.65.4.897","article-title":"Glutathione S- transferase M1 and multidrug resistance protein 1 act in synergy to protect melanoma cells from vincristine effects","volume":"65","author":"Depeille","year":"2004","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.canlet.2021.06.004_bib140","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1093\/carcin\/bgs401","article-title":"RLIP76 is overexpressed in human glioblastomas and is required for proliferation, tumorigenesis and suppression of apoptosis","volume":"34","author":"Wang","year":"2013","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.canlet.2021.06.004_bib141","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13048-019-0510-8","article-title":"A potential function of RLIP76 in the ovarian corpus luteum","volume":"12","author":"Billhaq","year":"2019","journal-title":"J. Ovarian Res."},{"key":"10.1016\/j.canlet.2021.06.004_bib142","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s12013-014-0237-5","article-title":"RLIP76 blockade by siRNA inhibits proliferation, enhances apoptosis, and suppresses invasion in HT29 colon cancer cells","volume":"71","author":"Zhang","year":"2015","journal-title":"Cell Biochem. Biophys."},{"key":"10.1016\/j.canlet.2021.06.004_bib143","doi-asserted-by":"crossref","first-page":"5172","DOI":"10.1158\/0008-5472.CAN-06-3669","article-title":"Melanocyte expression of survivin promotes development and metastasis of UV-induced melanoma in HGF-transgenic mice","volume":"67","author":"Thomas","year":"2007","journal-title":"Canc. Res."},{"key":"10.1016\/j.canlet.2021.06.004_bib144","doi-asserted-by":"crossref","first-page":"41380","DOI":"10.1074\/jbc.M305766200","article-title":"Cells preconditioned with mild, transient UVA irradiation acquire resistance to oxidative stress and UVA-induced apoptosis: role of 4-hydroxynonenal in UVA-mediated signaling for apoptosis","volume":"278","author":"Yang","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2021.06.004_bib145","doi-asserted-by":"crossref","first-page":"41213","DOI":"10.1074\/jbc.M106838200","article-title":"Accelerated metabolism and exclusion of 4-hydroxy-nonenal through induction of RLIP76 and hGST5.8 is an early adaptive response of cells to heat and oxidative stress","volume":"276","author":"Cheng","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2021.06.004_bib146","doi-asserted-by":"crossref","first-page":"17259","DOI":"10.1074\/jbc.M700075200","article-title":"The Wnt5A\/protein kinase C pathway mediates motility in melanoma cells via the inhibition of metastasis suppressors and initiation of an epithelial to mesenchymal transition","volume":"282","author":"Dissanayake","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2021.06.004_bib147","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1038\/jid.2008.423","article-title":"Increasing burden of melanoma in the United States","volume":"129","author":"Linos","year":"2009","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.canlet.2021.06.004_bib148","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/0190-9622(90)70214-3","article-title":"Years of potential life lost: another indicator of the impact of cutaneous malignant melanoma on society","volume":"23","author":"Albert","year":"1990","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.canlet.2021.06.004_bib149","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/sj.bjc.6604891","article-title":"Integrating BRAF\/MEK inhibitors into combination therapy for melanoma","volume":"100","author":"Smalley","year":"2009","journal-title":"Br. J. Canc."},{"key":"10.1016\/j.canlet.2021.06.004_bib150","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1038\/s41467-020-15546-9","article-title":"Pre-clinical modeling of cutaneous melanoma","volume":"11","author":"Rebecca","year":"2020","journal-title":"Nat. Commun."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383521002871?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383521002871?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T15:57:38Z","timestamp":1759593458000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383521002871"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":150,"alternative-id":["S0304383521002871"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2021.06.004","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting the mercapturic acid pathway for the treatment of melanoma","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2021.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}